Eli Lilly and
$1,142.85Change from previous close: −0.61%Absolute change: −$7.00
At a glance
- Revenue growth
- +44.70%
- 2025 vs 2024
- Net income growth
- +94.90%
- 2025 vs 2024
- Net margin
- 31.7%
- 2024: 23.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 10,690 | 5,333 | 3,225 | 8,836 | 3,087 | 1,666 | 2,474 | 3,712 | 1,466 | 1,166 | -312 | 2,190 |
| Depreciation and amortization | 534 | 509 | 586 | 470 | 478 | 463 | 485 | 467 | 414 | 401 | 388 | 411 |
| Capital expenditure | -2,933 | -2,326 | -2,547 | -2,088 | -1,697 | -1,510 | -1,496 | -1,351 | -1,225 | -986 | -1,071 | -970 |
| Investing cash flow | -15,396 | -3,916 | -2,802 | -2,983 | -1,834 | -3,353 | -1,921 | -4,005 | -2,199 | -1,178 | -2,924 | -3,081 |
| Financing cash flow | 8,426 | -3,470 | -2,879 | 531 | -1,245 | 1,380 | -226 | 211 | 1,556 | -311 | 3,545 | 572 |
| Dividends paid | -1,546 | -1,548 | -1,346 | -1,345 | -1,347 | -1,346 | -1,168 | -1,171 | -1,172 | -1,169 | -1,018 | -1,016 |
| Share repurchases | -1,601 | -2,356 | -1,508 | -708 | -692 | -1,200 | -2,054 | -446 | — | — | — | — |
| Debt issued | 12,450 | 1,775 | -0.2 | 6,706 | 0.0 | 6,461 | -0.1 | 4,965 | 0.0 | 6,453 | 4,594 | 97.0 |
| Debt repaid | -873 | -750 | -0.3 | -4,092 | 825 | -1,849 | 3,042 | -3,089 | 2,736 | -5,205 | — | 1,498 |
| Effect of exchange rates | -52.0 | 67.0 | -67.1 | 31.7 | 275 | 132 | -429 | 227 | -59.6 | -35.5 | 129 | 5.3 |
| Net change in cash | 3,668 | -1,986 | -2,524 | 6,416 | 283 | -175 | -101 | 145 | 763 | -358 | 438 | -314 |
| Free cash flow | 7,757 | 3,007 | 678 | 6,748 | 1,390 | 156 | 978 | 2,361 | 241 | 180 | -1,383 | 1,219 |
| Levered free cash flow | 3,777 | 2,115 | 1,948 | 2,225 | 1,884 | -5,091 | 1,681 | -1,421 | 2,368 | -2,047 | -1,082 | -341 |